北新路橋(002307.SZ)披露業績快報 2019年度淨利升5.09%至5583.62萬元
格隆匯2月18日丨北新路橋(002307.SZ)披露2019年度業績快報,實現營業總收入106.89億元,同比增長4.25%;利潤總額2.02億元,同比增長55.93%;歸屬於上市公司股東的淨利潤5583.62萬元,同比增長5.09%;基本每股收益0.0622元。
報告期內,公司持續推進前期承攬的PPP、BOT等重大項目,業務規模擴大,收入增加。公司不斷提高項目營運水平,營業利潤和利潤總額實現增長,公司整體經營情況良好,財務狀況較為穩定。營業利潤較期初增加44.96%、利潤總額較期初增加55.93%,主要原因是報告期內,公司業務規模擴大,收入增加所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.